Immunotherapy utilizing checkpoint inhibitors has fundamentally transformed treatment for advanced melanoma and other cutaneous malignancies. These monoclonal antibodies targeting immune checkpoint proteins (PD-1, PD-L1, CTLA-4) release inhibitory signals suppressing T cell responses, enabling immune system to recognize and eliminate cancer cells. Checkpoint inhibitors demonstrate remarkable activity in metastatic melanoma with response rates of 40% to 60%, substantially exceeding traditional chemotherapy. The mechanism of immune activation also enables treatment of immunologically "cold" tumors previously resistant to systemic therapy.
Checkpoint Pathways and Immune Evasion
Malignant cells express ligands (PD-L1, PD-L2) binding to inhibitory receptors (PD-1) on T cells, effectively "turning off" antitumor immunity. This mechanism of immune evasion allows cancer to persist despite T cell infiltration. Checkpoint inhibitors block these interactions, restoring T cell activation. Pembrolizumab and nivolumab target PD-1; atezolizumab and durvalumab target PD-L1; ipilimumab targets CTLA-4, another inhibitory checkpoint. Different checkpoint pathways regulate immunity at different anatomical sites and disease stages; sequential or combination approaches may provide superior benefit compared to monotherapy.
CTLA-4 functions as early checkpoint regulating T cell activation in lymph nodes; PD-1 operates as late checkpoint suppressing T cells within tumor microenvironment. This distinction explains rationale for combination therapy: ipilimumab (anti-CTLA-4) priming T cells in secondary lymphoid organs combined with nivolumab (anti-PD-1) releasing suppression within tumors achieves superior response rates compared to monotherapy.
Efficacy in Melanoma and Response Patterns
PD-1 Inhibitor Monotherapy: Nivolumab (240 milligrams every 2 weeks or 480 milligrams every 4 weeks) and pembrolizumab (200 milligrams every 3 weeks or 400 milligrams every 6 weeks) achieve response rates of 30% to 40% in metastatic melanoma. Complete response occurs in 5% to 10% of patients; partial responses account for majority of benefit. Median progression-free survival approximates 4 to 6 months; median overall survival reaches 15 to 18 months with durable responses in some patients extending years.
CTLA-4 Inhibitor Monotherapy: Ipilimumab (3 milligrams per kilogram intravenously every 3 weeks for 4 doses, then maintenance) achieves response rates of 10% to 15%. Response lag necessitates alternative response assessment (irRECIST) accounting for pseudoprogression where tumors initially increase before subsequent response. Ipilimumab monotherapy shows more modest single-agent activity compared to PD-1 inhibitors.
Combination Therapy: Nivolumab (1 milligram per kilogram) plus ipilimumab (3 milligrams per kilogram) achieves response rates of 50% to 60%, substantially exceeding monotherapy. However, combination therapy significantly increases immune-related adverse event rates (70% to 90% versus 40% to 50% for monotherapy). Complete response rates reach 10% to 15% with combination therapy. Median progression-free survival reaches 9 to 11 months and median overall survival reaches 25 to 37 months.
Immune-Related Adverse Events (irAEs)
Checkpoint inhibitors cause immune-related adverse events through enhanced T cell activation. Dermatologic manifestations occur frequently (20% to 30% of patients) including rash, vitiligo, and lichenoid eruptions. Gastrointestinal toxicity (diarrhea, colitis) affects 20% to 30% of PD-1 inhibitor recipients and up to 50% of combination therapy patients. Hepatotoxicity, pneumonitis, and endocrinopathy (hypothyroidism, thyroid dysfunction) occur in 10% to 20% of patients. Severe irAEs (grade 3 or 4) affect approximately 25% of monotherapy patients and 55% to 60% of combination therapy recipients.
Grade 3 or 4 irAEs typically necessitate immune checkpoint inhibitor discontinuation and initiation of systemic corticosteroids. Prednisone or methylprednisolone at 1 to 2 milligrams per kilogram daily, tapered over 4 to 8 weeks, controls most irAEs. Refractory cases may require additional immunosuppression including mycophenolate mofetil or infliximab. Most irAEs resolve with appropriate management, though some toxicities (endocrinopathy, hypophysitis) may persist or recur after immunosuppression discontinuation.
Immune checkpoint inhibitor rechallenge after irAE resolution remains controversial. Some patients tolerate rechallenge without recurrent toxicity; others experience recurrence. Individual assessment of benefit-risk ratio guides decisions regarding retreatment.
Treatment Selection and Combination with Targeted Therapy
First-Line Treatment Selection: PD-1 inhibitor monotherapy represents standard first-line treatment for metastatic melanoma based on superior efficacy and better tolerability profile compared to CTLA-4 inhibitors. Combination therapy shows superior response rates but increased toxicity; combination therapy may be preferred for rapidly progressive disease or patients able to tolerate increased side effects.
BRAF-Mutated Melanoma: BRAF/MEK inhibitor combination therapy (dabrafenib 150 milligrams twice daily plus trametinib 2 milligrams daily) demonstrates rapid response but frequent development of resistance within 6 to 11 months. Sequential therapy combining initial targeted therapy for rapid disease control followed by immunotherapy upon resistance represents optimal approach for many patients. Combination targeted therapy plus immunotherapy shows benefit but substantially increased toxicity.
Adjuvant Therapy: Adjuvant checkpoint inhibitor therapy improves recurrence-free survival in stage III melanoma with lymph node involvement. Nivolumab (3 milligrams per kilogram every 2 weeks for 12 months) and ipilimumab (10 milligrams per kilogram every 3 weeks for 4 doses, then every 12 weeks for 3 years) each improve three-year recurrence-free survival compared to observation. Combination adjuvant therapy may provide superior benefit but requires careful patient selection given toxicity.
Biomarkers Predicting Immunotherapy Response
PD-L1 expression on tumor cells correlates with immunotherapy response; PD-L1-positive melanomas show response rates of 40% to 50% versus 20% to 30% for PD-L1-negative tumors. However, approximately 30% to 40% of PD-L1-negative patients still respond to immunotherapy; PD-L1 status does not definitively predict non-response.
Tumor mutational burden (TMB), reflecting number of somatic mutations per megabase of genomic DNA, predicts immunotherapy response. High-TMB melanomas (greater than 10 mutations per megabase) show response rates of 50% to 60%; low-TMB melanomas show rates of 20% to 30%. However, TMB assessment requires genomic sequencing not routinely available clinically. Microbiome composition, neoantigen burden, and immune cell infiltration patterns also correlate with response.
FAQ
How long do I need to take immunotherapy?
For metastatic melanoma, immunotherapy continues indefinitely until disease progression or unacceptable toxicity. Some patients achieve complete response that persists after discontinuation; others require continued treatment indefinitely to maintain response. Adjuvant therapy duration varies: adjuvant nivolumab lasts 12 months; adjuvant ipilimumab lasts 3 years. Treatment duration decisions must be individualized based on response and tolerability.
What are typical dosages for checkpoint inhibitor therapy?
Nivolumab is dosed at 3 milligrams per kilogram every 2 weeks (adjuvant) or 240 milligrams every 2 weeks (metastatic). Pembrolizumab is dosed at 200 milligrams every 3 weeks or 400 milligrams every 6 weeks. Ipilimumab is dosed at 3 milligrams per kilogram every 3 weeks for 4 doses as monotherapy or 1 milligram per kilogram with nivolumab for combination therapy. Dosing may be adjusted based on body weight, renal function, and liver function.
Can immunotherapy be used for early-stage melanoma?
Yes. Adjuvant checkpoint inhibitor therapy improves outcomes in stage III melanoma with lymph node involvement. Adjuvant nivolumab and ipilimumab, approved for this indication, improve recurrence-free survival compared to observation. Adjuvant therapy proves particularly valuable for high-risk features including lymph node involvement, ulceration, or high mitotic rate.
What should I do if I develop immune-related side effects from immunotherapy?
Report symptoms to oncology or dermatology team immediately. Mild rash or diarrhea may be managed conservatively with topical treatments or antimotility agents. Severe symptoms require immunotherapy discontinuation and systemic corticosteroids (prednisone 1 to 2 milligrams per kilogram daily, tapered over weeks). Most immune-related adverse events resolve completely with appropriate management, though some may persist.
References
1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine. 2015;373(1):23-34. Pivotal trial establishing combination immunotherapy benefit.
2. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New England Journal of Medicine. 2015;372(4):320-330. PD-1 inhibitor monotherapy efficacy data.
3. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo in resected stage III-IV melanoma. New England Journal of Medicine. 2015;372(26):2521-2532. Adjuvant immunotherapy benefit demonstration.
4. Weber JS, D'Angelo SP, Minor D, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C melanoma. New England Journal of Medicine. 2017;377(19):1824-1835. Comparative adjuvant therapy data.
5. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New England Journal of Medicine. 2015;372(21):2006-2017. Combination versus monotherapy comparison.
6. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. New England Journal of Medicine. 2013;369(2):122-133. Early combination immunotherapy trial data.
7. Nishino M, Giobbie-Hurder A, Garg K, et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clinical Cancer Research. 2016;22(8):1993-2000. Novel response assessment methodology for immunotherapy.
8. Gide TN, Wilmott JS, Scolyer RA, Long GV. Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clinical and Experimental Immunology. 2018;191(2):107-117. Mechanisms of resistance to checkpoint inhibition.
9. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. Journal of Clinical Oncology. 2018;36(17):1714-1768. Toxicity management guidelines.
10. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncology. 2016;17(12):e542-e551. Biomarker development for response prediction.